P1102 (DAIDS ID 10619): Strategic Timing of AntiRetroviral Treatment

Study Status Study Restriction

Closed to Accrual

United States


What is P1102?

INSIGHT's START (Strategic Timing of AntiRetroviral Treatment) is an international randomized trial to determine whether starting antiretroviral therapy (ART) early (before CD4 drops to less than 500 cells/mm³), rather than waiting until CD4 drops to less than 350 cells/mm³ (when evidence from randomized trials supports starting ART), reduces the occurrence of serious morbidity and mortality. Go to the START website


Sites where the study is implemented:

CRS ID Site Name City Country
No records returned.

Study contacts:

Study Co-chair: Abdel Babiker

Study Co-chair: Fred Gordin

Study Co-chair: Jens Lundgren

CTS: Anne Coletti


Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.